据了解，�?��-唾液酸乳糖钠盐是由大肠杆菌W (ATCC 9637)的衍生菌株（大肠杆菌NEO3）生产的。经过评估，专家小组得出结论，在提议的使用条件下�?��-唾液酸乳糖钠盐作为新型食品是安全的。部分原文报道如下：

　　Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3��-sialyllactose (3��-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 3��-SL (sodium salt), but it also co ntains sialic acid, d-glucose, d-lactose, 3��-sialyllactulose and 6��-sialyllactose sodium salts and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli NEO3) of E. coli W (ATCC 9637). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements (FS). The target population is the general population. The applicant applies for the same uses and use levels as already assessed for 3��-SL sodium salt produced by a genetically modified strain of E. coli K-12 DH1, with the exception for the use in FS, which is proposed to be higher (from 0.5 to 1.0 g/day) in individuals from 3 years of age. Since the NF as a food ingredient would be co nsumed at the same extent as the already assessed 3��-SL sodium salt, no new estimates of the intakes have been carried out. The Panel notes that the maximum daily intake of 3��-SL from the proposed use of the NF in FS for individuals from 3 years of age (1.0 g/day) is lower than the estimated highest mean daily intake of 3��-SL in breastfed infants. FS are not intended to be used if other sources of 3��-SL are co nsumed on the same day. The Panel co ncludes that the NF is safe under the proposed co nditions of use.

　　 本文由食品伙伴网食品资讯中心编辑，供网友参考，有任何疑问，请联系news@www.sqrdapp.com、�/span>